Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd
NAICS : 325412
ISIN : CNE000000X38
Share Class Description:
SHSE:600196: Class ACompare
Compare
Traded in other countries / regions
600196.China02196.Hong KongSFOSF.USA08HH.Germany IPO Date
1998-08-07Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.51 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.74 | |||||
| Debt-to-EBITDA | 5.61 | |||||
| Interest Coverage | 2.68 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.61 | |||||
| Beneish M-Score | -2.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.6 | |||||
| 3-Year EBITDA Growth Rate | 2.9 | |||||
| 3-Year EPS without NRI Growth Rate | 3.2 | |||||
| 3-Year FCF Growth Rate | -30.4 | |||||
| 3-Year Book Growth Rate | 10.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.38 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.44 | |||||
| 9-Day RSI | 55.43 | |||||
| 14-Day RSI | 51.32 | |||||
| 6-1 Month Momentum % | -12.6 | |||||
| 12-1 Month Momentum % | -4.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1 | |||||
| Quick Ratio | 0.79 | |||||
| Cash Ratio | 0.47 | |||||
| Days Inventory | 115.59 | |||||
| Days Sales Outstanding | 64.39 | |||||
| Days Payable | 99.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.47 | |||||
| 3-Year Dividend Growth Rate | 20.5 | |||||
| Forward Dividend Yield % | 1.47 | |||||
| 5-Year Yield-on-Cost % | 2.23 | |||||
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | -4.22 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.34 | |||||
| Operating Margin % | 6.88 | |||||
| Net Margin % | 9.03 | |||||
| ROE % | 9.15 | |||||
| ROA % | 3.75 | |||||
| ROIC % | 2.83 | |||||
| ROC (Joel Greenblatt) % | 32.84 | |||||
| ROCE % | 8.25 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.07 | |||||
| Forward PE Ratio | 15.55 | |||||
| PE Ratio without NRI | 19.07 | |||||
| Shiller PE Ratio | 21.2 | |||||
| PEG Ratio | 2.44 | |||||
| PS Ratio | 1.73 | |||||
| PB Ratio | 1.68 | |||||
| Price-to-Tangible-Book | 4.3 | |||||
| Price-to-Operating-Cash-Flow | 17.94 | |||||
| EV-to-EBIT | 14.4 | |||||
| EV-to-Forward-EBIT | 26.05 | |||||
| EV-to-EBITDA | 14.4 | |||||
| EV-to-Forward-EBITDA | 16.01 | |||||
| EV-to-Revenue | 1.97 | |||||
| EV-to-Forward-Revenue | 1.72 | |||||
| EV-to-FCF | -43.1 | |||||
| Price-to-Projected-FCF | 3.45 | |||||
| Price-to-DCF (Earnings Based) | 1.37 | |||||
| Price-to-Median-PS-Value | 0.44 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.03 | |||||
| Price-to-Graham-Number | 1.91 | |||||
| Earnings Yield (Greenblatt) % | 6.94 | |||||
| Forward Rate of Return (Yacktman) % | 4.63 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Fosun Pharmaceutical (Group) Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 43,999.141 | ||
| EPS (TTM) (Â¥) | 1.5 | ||
| Beta | 0.51 | ||
| Volatility % | 22.76 | ||
| 14-Day RSI | 51.32 | ||
| 14-Day ATR (Â¥) | 0.468251 | ||
| 20-Day SMA (Â¥) | 28.218 | ||
| 12-1 Month Momentum % | -4.26 | ||
| 52-Week Range (Â¥) | 27.4 - 40.68 | ||
| Shares Outstanding (Mil) | 2,672.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Fosun Pharmaceutical (Group) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Fosun Pharmaceutical (Group) Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Fosun Pharmaceutical (Group) Co Ltd Frequently Asked Questions
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd(SHSE:600196)'s stock price today?
The current price of SHSE:600196 is ¥28.60. The 52 week high of SHSE:600196 is ¥40.68 and 52 week low is ¥27.40.
When is next earnings date of Shanghai Fosun Pharmaceutical (Group) Co Ltd(SHSE:600196)?
The next earnings date of Shanghai Fosun Pharmaceutical (Group) Co Ltd(SHSE:600196) is .
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd(SHSE:600196) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Fosun Pharmaceutical (Group) Co Ltd(SHSE:600196) is 1.47% (As of Today), Highest Dividend Payout Ratio of Shanghai Fosun Pharmaceutical (Group) Co Ltd(SHSE:600196) was 0.39. The lowest was 0.23. And the median was 0.27. The  Forward Dividend Yield % of Shanghai Fosun Pharmaceutical (Group) Co Ltd(SHSE:600196) is 1.47%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers